Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group differenc...
Publications
2 shownOral Rivaroxaban for Symptomatic Venous Thromboembolism
Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation....
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 12,363
- Institution
- Bayer (United States)
External Links
Identifiers
- ORCID
- 0000-0002-9428-4408
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.